Pharma Pulse: DHL's New Cold Chain Corridors and Walmart's $0 Prescription Tier

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines.

First up, DHL Global Forwarding is extending its dedicated healthcare air network into Asia. The company added six Life Sciences & Healthcare corridors to its DHL Health Logistics Cold Chain Network: Liège–Shanghai, Brussels–Shanghai, Brussels–Singapore, Cincinnati–Singapore, Cincinnati–Tokyo Narita and Cincinnati–Seoul Incheon.¹ Most flights operate on DHL's own branded aircraft, which keeps shipments inside its network and reduces handovers, and the company deploys Boeing 777 freighters with three compartments set to separate temperatures. The corridors use thermal blanket solutions, and DHL pairs blankets with phase change materials across the network as a controlled, cost-competitive option for biologics, vaccines and clinical trial materials.

“We are responding to our customers' demand for reliable connections between key healthcare markets and enabling even better control of critical quality parameters throughout the entire transport process,” said Henk Venema, global head of air freight at DHL Global Forwarding.¹

The routes follow the Brussels–Cincinnati corridor launched earlier this year, and the two Singapore lanes build on DHL's investments there, including the future DHL Singapore Cold Chain Hub. For shippers, more dedicated lanes add another variable to how lanes and duration shape cold chain packaging selection.

Next, the country's largest private employer is redrawing how its workers reach prescription drugs, and the design choices carry signals for manufacturers. Starting Jan. 1, 2027, Walmart will add a Zero Dollar prescription tier for its 1.6 million US associates, covering more than 250 generic, brand-name and specialty medications, including some insulins and inhalers. Walmart says the tier prioritizes medications at lower costs.² It is also adding a Rare Conditions Center of Excellence that gives associates no-cost access to specialists at facilities such as Mayo Clinic and Cleveland Clinic for multiple sclerosis, Parkinson's disease and ALS, with travel covered for the patient and an adult caregiver.² Additionally, the employer announced it will offer certain GLP-1 medications for Type 2 diabetes at no cost to eligible employees.

For manufacturers, the signal is in the design. Because the $0 tier includes brand and specialty drugs and favors lower-cost options, a product’s cost position now affects whether patients pay anything for it. The Rare Conditions COE, meanwhile, gives specialists at major institutions an early say in MS, Parkinson’s and ALS treatment.

Lastly, rare disease is also drawing fresh attention in Washington. The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose approach to rare disease drug development, matching requirements to each disease, product type and the evidence small patient populations can realistically produce.³ With only about 5% of rare conditions having an approved treatment, the agency committed to clearer guidance, earlier patient input, novel statistical methods and risk-based chemistry, manufacturing and controls (CMC) review and pre-approval inspections.

“This new framework will enhance consistency and predictability for both sponsors and for patients,” said Amy Comstock Rick, director of the agency’s Rare Disease Innovation Hub.³

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening, until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.

References

1. DHL Group. "DHL expands Cold Chain Network with six new dedicated healthcare corridors connecting Europe and North America to Asia." October 12, 2026. https://group.dhl.com/en/media-relations/press-releases/2026/dhl-expands-cold-chain-network.html
2. Walmart. "Keeping Affordable Healthcare Within Reach." October 13, 2026. https://corporate.walmart.com/news/2026/10/keeping-affordable-healthcare-within-reach
3. US Food and Drug Administration. "FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development." October 14, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease